Equities

CRUSHMETRIC Group Ltd

CUSH:NXX

CRUSHMETRIC Group Ltd

Actions
  • Price (GBX)35.00
  • Today's Change0.00 / 0.00%
  • Shares traded1.43k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Aug 01 2018.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

CRUSHMETRIC Group Ltd is a United Kingdom-based holding company of a group engaged in the provision of traditional Chinese medicine (TCM) healthcare services, including consultations and TCM therapies, through a network of clinics in Hong Kong, and the sale and distribution of TCM healthcare and skincare products through wholesale outlets and TCM clinics, its retail store in Hong Kong and other non-related TCM retail stores, as well as directly to customers through its online store. It operates through two business segments: Sales of TCM and healthcare and skincare products, and Provision of TCM healthcare services. Its Rorrico is a TCM product for the treatment of influenza viruses, including the Influenza A virus and its sub-type virus, pandemic H1N1 or Swine flu. Rorrico's formula contains approximately 20 herbs. It is confected with honeysuckle, radix isatidis, rhubarb, codonopsis pilosula, amomum villosum, malt and white atractylodes medicine.

  • Revenue in GBP (TTM)888.99k
  • Net income in GBP-6.74m
  • Incorporated2010
  • Employees20.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kanabo Group PLC1.14m-8.18m6.32m17.00--1.07--5.55-0.013-0.0130.00180.00940.105416.2843.8567,058.82-75.70-75.83-81.16-83.337.89---718.33-1,267.352.72-63.430.0337--48.42---16.26------
Oncimmune Holdings PLC1.21m-3.14m17.27m33.00------14.22-0.04230.09580.0164-0.01720.17561.190.691736,787.88-45.43------63.34---258.65--1.01-0.65111.32--------------
Celadon Pharmaceuticals PLC130.00k-5.23m18.24m----7.20--140.34-0.0827-0.08270.0020.03680.014526.790.1194---58.39---67.06---3,433.85---4,024.62--1.56-8.760.6608--212.50--58.01------
CRUSHMETRIC Group Ltd888.99k-6.74m30.16m20.00--1.62--33.92-0.0239-0.02390.00340.07720.03286.1315.64---25.27-25.22-31.29-56.6673.0641.64-771.01-200.760.0273-3.180.0802---36.42-8.40-1,096.05---29.47--
Eco Animal Health Group Plc89.42m1.05m47.77m222.0049.890.57079.950.53420.01410.01411.291.240.73122.632.98402,801.801.644.562.296.2242.1445.402.255.922.297.460.04135.374.825.863.97-32.082.71--
Venture Life Group PLC51.41m742.00k52.73m165.00105.870.70715.441.030.00390.00390.38470.58690.44532.673.92311,575.800.64271.580.71721.8339.6240.141.443.991.422.160.22150.0016.8922.3377.1231.3018.85--
Animalcare Group Plc74.55m4.69m141.88m226.0030.341.4611.421.900.07750.30331.231.610.62872.765.63329,885.003.960.32724.710.386657.8254.926.300.54842.677.170.0425599.953.820.5138-38.98---11.792.59
Data as of Aug 01 2018. Currency figures normalised to CRUSHMETRIC Group Ltd's reporting currency: UK Pound GBX
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.